Medication topics
Ustekinumab articles covering Stelara, IL-12/23 therapy, biosimilars, safety, approvals, access, and IBD treatment decisions. Medication context emphasizes treatment decisions, safety, approvals, and therapy access.
Page 2 of 2 · 50 articles
An FDA approval means another biologic option is available for Crohn’s disease, which could affect treatment choices and insurance coverage. The approval also signals pharma competition and pipeline activity that may...
A new FDA approval means another IL-23 option is formally available for people with moderately to severely active Crohn’s disease, including patients whose disease did not respond to other therapies. This could affect...
